3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
14
Nivolumab
10
atezolizumab
5
durvalumab
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
avelumab
3
Specimen Handling
3
Radiosurgery
3
Magnetic Resonance Spectroscopy
3
temsirolimus
2
poly ICLC
2
fludarabine
2
epacadostat
2
enzalutamide
2
cabozantinib
2
budigalimab
2
aldesleukin
2
abiraterone
2
Radiotherapy
2
Interleukin-2
2
Gemcitabine
2
venetoclax
1
utomilumab
1
trastuzumab deruxtecan
1
tislelizumab
1
spartalizumab
1
sargramostim
1
rovalpituzumab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
High-Intensity Focused Ultrasound Ablation
×
Dermatologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled